secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001104659-25-020349
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics raises $14M in registered direct offering with warrants
----------------------------------------------------------------------------

- Total gross proceeds of $14M from sale of 188,383 shares and pre-funded warrants for up to 3,811,617 shares.
- Combined offering price: $3.50 per share + accompanying warrant; $3.499 per pre-funded warrant + accompanying warrant.
- Warrants exercisable at $4.20 per share; option warrants to purchase up to 4,000,000 additional shares.
- Placement agent Rodman & Renshaw receives a 6.0% cash fee on gross proceeds.
- Closing expected on first Trading Day after March 3, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925020349/0001104659-25-020349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925020349/tm258193-1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-020349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer